Graham Capital Management L.P. Has $267,000 Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Graham Capital Management L.P. decreased its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 18.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,200 shares of the biopharmaceutical company’s stock after selling 737 shares during the quarter. Graham Capital Management L.P.’s holdings in Intra-Cellular Therapies were worth $267,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its stake in Intra-Cellular Therapies by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock valued at $1,878,000 after buying an additional 2,157 shares in the last quarter. Barclays PLC boosted its stake in Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after purchasing an additional 25,435 shares in the last quarter. Oak Ridge Investments LLC boosted its stake in Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock worth $1,656,000 after purchasing an additional 8,440 shares in the last quarter. Merit Financial Group LLC acquired a new position in Intra-Cellular Therapies in the fourth quarter worth $206,000. Finally, SG Americas Securities LLC boosted its stake in Intra-Cellular Therapies by 204.4% in the fourth quarter. SG Americas Securities LLC now owns 12,917 shares of the biopharmaceutical company’s stock worth $1,079,000 after purchasing an additional 8,673 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Intra-Cellular Therapies stock opened at $131.87 on Friday. The business’s 50-day simple moving average is $131.79 and its 200 day simple moving average is $114.01. The stock has a market cap of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 12-month low of $64.09 and a 12-month high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. As a group, sell-side analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on ITCI. Canaccord Genuity Group lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Royal Bank of Canada reissued a “sector perform” rating and issued a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $132.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Intra-Cellular Therapies presently has an average rating of “Hold” and a consensus price target of $109.70.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.